Literature DB >> 7126898

Clinico-pathological correlates in ovarian cancer.

A J Dembo, R S Bush, T C Brown.   

Abstract

Multivariate analysis was performed on prognostic data derived from 810 patients with invasive ovarian cancer treated between 1971 and 1978. An examination of the prognostic significance of grade and pathologic subtype revealed that grade was strongly prognostic for serous tumors. In mucinous and endometrioid tumors however, the effect of grade was quite weak; furthermore, the prognostic significance of mucinous and endometrioid tumors did not differ from each other and was intermediate between well and poorly (or moderately) differentiated serous tumors. The compound pathology-grade classification derived from this analysis as well as the amount of macroscopic tumor residuum and the anatomic stage, were shown to exert a powerful prognostic effect independent of each other. Combining the information derived from all of these variables permits enhanced treatment selection to a degree which is not possible when each factor is considered on its own.

Entities:  

Mesh:

Year:  1982        PMID: 7126898

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  4 in total

1.  Postoperative abdominopelvic irradiation in patients with epithelial cancer of ovary. The Princess Margaret Hospital Experience.

Authors:  A J Dembo
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

2.  Radiation therapy in the treatment of patients with cancer of the ovary.

Authors:  R S Bush
Journal:  Bull N Y Acad Med       Date:  1983-10

3.  Morphometric data to FIGO stage and histological type and grade for prognosis of ovarian tumours.

Authors:  J P Baak; E C Wisse-Brekelmans; F A Langley; A Talerman; J F Delemarre
Journal:  J Clin Pathol       Date:  1986-12       Impact factor: 3.411

4.  A prognostic model for ovarian cancer.

Authors:  T G Clark; M E Stewart; D G Altman; H Gabra; J F Smyth
Journal:  Br J Cancer       Date:  2001-09-28       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.